Deficiencies of methods applied in cost effectiveness analysis of hematological malignancies

Nicolas Batty; Joseph Shatzel; Samuel Wiles; Mathew Kabalan; Rohit Sharma; Jonathan Pang; David Yi; Iris Alatovic; Sana Saif; Deepika Narasimha; Joseph LaPenna; Anthony Troitino; Kristopher Attwood; Michael Weinstein; Eric Murawski; Mathew Valerio; Yong Yin; Meir Wetzler

doi:10.1016/j.jcpo.2014.01.002

Deficiencies of methods applied in cost effectiveness analysis of hematological malignancies

Nicolas Batty, Joseph Shatzel, Samuel Wiles, Mathew Kabalan, Rohit Sharma, Jonathan Pang, David Yi, Iris Alatovic, Sana Saif, Deepika Narasimha, Joseph LaPenna, Anthony Troitino, Kristopher Attwood, Michael Weinstein, Eric Murawski, Mathew Valerio, Yong Yin, Meir Wetzler

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Background: As novel therapies in oncology and in particular hematological malignancies impose a high financial burden with a limited increase in life expectancy. Therefore, CEA is important to evaluate the value of new therapies. However, there is a dire need to critically evaluate how valid are such studies. Aims: To review and critically analyze the methodology used to conduct CEAs within the hematologic malignancies disease. Methods: We conducted a PubMed search using the following keywords and combined searches: CEAs, hematological malignancies leukemia, lymphoma and myeloma. Results: Available data showed that systemic reviews of CEA of hematological malignancies to assess whether reviewers have not sufficiently cited deficiencies in their methodologies, or stated clearly the impact of sponsorship and publication biases. Conclusion: Despite the paucity of the literature, sponsorship bias was found to be a major concern in the validity of these analyses.

Original language	English (US)
Pages (from-to)	40-44
Number of pages	5
Journal	Journal of Cancer Policy
Volume	2
Issue number	2
DOIs	https://doi.org/10.1016/j.jcpo.2014.01.002
State	Published - Jun 2014
Externally published	Yes

Keywords

Cost effectiveness analysis
Deficiencies
Hematological malignancies
Methodologies
Oncology

ASJC Scopus subject areas

Oncology
Health Policy

Access to Document

10.1016/j.jcpo.2014.01.002

Cite this

Batty, N., Shatzel, J., Wiles, S., Kabalan, M., Sharma, R., Pang, J., Yi, D., Alatovic, I., Saif, S., Narasimha, D., LaPenna, J., Troitino, A., Attwood, K., Weinstein, M., Murawski, E., Valerio, M., Yin, Y., & Wetzler, M. (2014). Deficiencies of methods applied in cost effectiveness analysis of hematological malignancies. Journal of Cancer Policy, 2(2), 40-44. https://doi.org/10.1016/j.jcpo.2014.01.002

Batty, N, Shatzel, J, Wiles, S, Kabalan, M, Sharma, R, Pang, J, Yi, D, Alatovic, I, Saif, S, Narasimha, D, LaPenna, J, Troitino, A, Attwood, K, Weinstein, M, Murawski, E, Valerio, M, Yin, Y & Wetzler, M 2014, 'Deficiencies of methods applied in cost effectiveness analysis of hematological malignancies', Journal of Cancer Policy, vol. 2, no. 2, pp. 40-44. https://doi.org/10.1016/j.jcpo.2014.01.002

@article{2953fa86b0784c7e9574459130d58dc6,

title = "Deficiencies of methods applied in cost effectiveness analysis of hematological malignancies",

abstract = "Background: As novel therapies in oncology and in particular hematological malignancies impose a high financial burden with a limited increase in life expectancy. Therefore, CEA is important to evaluate the value of new therapies. However, there is a dire need to critically evaluate how valid are such studies. Aims: To review and critically analyze the methodology used to conduct CEAs within the hematologic malignancies disease. Methods: We conducted a PubMed search using the following keywords and combined searches: CEAs, hematological malignancies leukemia, lymphoma and myeloma. Results: Available data showed that systemic reviews of CEA of hematological malignancies to assess whether reviewers have not sufficiently cited deficiencies in their methodologies, or stated clearly the impact of sponsorship and publication biases. Conclusion: Despite the paucity of the literature, sponsorship bias was found to be a major concern in the validity of these analyses.",

keywords = "Cost effectiveness analysis, Deficiencies, Hematological malignancies, Methodologies, Oncology",

author = "Nicolas Batty and Joseph Shatzel and Samuel Wiles and Mathew Kabalan and Rohit Sharma and Jonathan Pang and David Yi and Iris Alatovic and Sana Saif and Deepika Narasimha and Joseph LaPenna and Anthony Troitino and Kristopher Attwood and Michael Weinstein and Eric Murawski and Mathew Valerio and Yong Yin and Meir Wetzler",

year = "2014",

month = jun,

doi = "10.1016/j.jcpo.2014.01.002",

language = "English (US)",

volume = "2",

pages = "40--44",

journal = "Journal of Cancer Policy",

issn = "2213-5383",

publisher = "Elsevier BV",

number = "2",

}

TY - JOUR

T1 - Deficiencies of methods applied in cost effectiveness analysis of hematological malignancies

AU - Batty, Nicolas

AU - Shatzel, Joseph

AU - Wiles, Samuel

AU - Kabalan, Mathew

AU - Sharma, Rohit

AU - Pang, Jonathan

AU - Yi, David

AU - Alatovic, Iris

AU - Saif, Sana

AU - Narasimha, Deepika

AU - LaPenna, Joseph

AU - Troitino, Anthony

AU - Attwood, Kristopher

AU - Weinstein, Michael

AU - Murawski, Eric

AU - Valerio, Mathew

AU - Yin, Yong

AU - Wetzler, Meir

PY - 2014/6

Y1 - 2014/6

N2 - Background: As novel therapies in oncology and in particular hematological malignancies impose a high financial burden with a limited increase in life expectancy. Therefore, CEA is important to evaluate the value of new therapies. However, there is a dire need to critically evaluate how valid are such studies. Aims: To review and critically analyze the methodology used to conduct CEAs within the hematologic malignancies disease. Methods: We conducted a PubMed search using the following keywords and combined searches: CEAs, hematological malignancies leukemia, lymphoma and myeloma. Results: Available data showed that systemic reviews of CEA of hematological malignancies to assess whether reviewers have not sufficiently cited deficiencies in their methodologies, or stated clearly the impact of sponsorship and publication biases. Conclusion: Despite the paucity of the literature, sponsorship bias was found to be a major concern in the validity of these analyses.

AB - Background: As novel therapies in oncology and in particular hematological malignancies impose a high financial burden with a limited increase in life expectancy. Therefore, CEA is important to evaluate the value of new therapies. However, there is a dire need to critically evaluate how valid are such studies. Aims: To review and critically analyze the methodology used to conduct CEAs within the hematologic malignancies disease. Methods: We conducted a PubMed search using the following keywords and combined searches: CEAs, hematological malignancies leukemia, lymphoma and myeloma. Results: Available data showed that systemic reviews of CEA of hematological malignancies to assess whether reviewers have not sufficiently cited deficiencies in their methodologies, or stated clearly the impact of sponsorship and publication biases. Conclusion: Despite the paucity of the literature, sponsorship bias was found to be a major concern in the validity of these analyses.

KW - Cost effectiveness analysis

KW - Deficiencies

KW - Hematological malignancies

KW - Methodologies

KW - Oncology

UR - http://www.scopus.com/inward/record.url?scp=84899995890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899995890&partnerID=8YFLogxK

U2 - 10.1016/j.jcpo.2014.01.002

DO - 10.1016/j.jcpo.2014.01.002

M3 - Review article

AN - SCOPUS:84899995890

SN - 2213-5383

VL - 2

SP - 40

EP - 44

JO - Journal of Cancer Policy

JF - Journal of Cancer Policy

IS - 2

ER -

Deficiencies of methods applied in cost effectiveness analysis of hematological malignancies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this